Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression

Investigational New Drugs

Volumn 30, Issue 1, 2012, Pages 25-36

  Palani, Chithra D ^a   Beck, James F ^a   Sonnemann, Jürgen ^a,b  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Histone deacetylase inhibitors; MDM2; MDM4; Nutlin 3; P53 acetylation; Paclitaxel

Indexed keywords

APICIDIN; BUTYRIC ACID; CASPASE 3; ENTINOSTAT; MESSENGER RNA; NUTLIN 3; PACLITAXEL; PROPIDIUM IODIDE; PROTEIN P53; VORINOSTAT;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CONTROLLED STUDY; DOWN REGULATION; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; IMMUNOBLOTTING; MITOCHONDRIAL MEMBRANE POTENTIAL; MURINE DOUBLE MINUTE 2 GENE; MURINE DOUBLE MINUTE 4 GENE; ONCOGENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; UPREGULATION; WILD TYPE;

ACETYLATION; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; BLOTTING, WESTERN; BUTYRATES; CELL DEATH; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SYNERGISM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; IMIDAZOLES; NEOPLASMS; NUCLEAR PROTEINS; PACLITAXEL; PEPTIDES, CYCLIC; PIPERAZINES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; PYRIDINES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84856520291     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9510-7     Document Type: Article

References (47)

1. Vousden KH, Lane DP (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8:275-283 (Pubitemid 46474662)
2. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP (2009) Awakening guardian angels: Drugging the p53 pathway. Nat Rev Cancer 9:862-873
3. Shangary S, Wang S (2009) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: A novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49:223-241
4. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844-848 (Pubitemid 38174664)
5. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, QingW, Packman K, Myklebost O, Heimbrook DC, Vassilev LT (2006) Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy. Proc Natl Acad Sci USA 103:1888-1893 (Pubitemid 43228788)
6. Hoffmann-La Roche (2007) A study of R7112 in patients with advanced solid tumors. In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US). http://clinicaltrials.gov/show/ NCT00559533. Accessed June 28, 2010. NLM Identifier: NCT00559533
7. Hoffmann-La Roche (2008) A study of R7112 in patients with hematologic neoplasms. In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US). http://clinicaltrials.gov/show/ NCT00623870. Accessed June 28, 2010. NLM Identifier: NCT00623870
8. Stimson L, Wood V, Khan O, Fotheringham S, La Thangue NB (2009) HDAC inhibitor-based therapies and haematological malignancy. Ann Oncol 20:1293-1302
9. Lane AA, Chabner BA (2009) Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27:5459-5468
10. Buchwald M, Kramer OH, Heinzel T (2009) HDACi-targets beyond chromatin. Cancer Lett 280:160-167
11. Richon VM, Garcia-Vargas J, Hardwick JS (2009) Development of vorinostat: Current applications and future perspectives for cancer therapy. Cancer Lett 280:201-210
12. Campas-Moya C (2009) Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today 45:787-795
13. Nolan L, Johnson PW, Ganesan A, Packham G, Crabb SJ (2008) Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? Br J Cancer 99:689-694
14. Wade M, Wahl GM (2009) Targeting Mdm2 and Mdmx in cancer therapy: Better living through medicinal chemistry? Mol Cancer Res 7:1-11
15. Kruse JP, Gu W (2009) Modes of p53 regulation. Cell 137:609-622
16. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W (2008) Acetylation is indispensable for p53 activation. Cell 133:612-626 (Pubitemid 351636297)
17. Luo J, Su F, Chen D, Shiloh A, Gu W (2000) Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408:377-381
18. Terui T, Murakami K, Takimoto R, Takahashi M, Takada K, Murakami T, Minami S, Matsunaga T, Takayama T, Kato J, Niitsu Y (2003) Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. Cancer Res 63:8948-8954 (Pubitemid 38064075)
19. Zhao Y, Lu S,Wu L, Chai G,Wang H, Chen Y, Sun J, Yu Y, ZhouW, Zheng Q, Wu M, Otterson GA, Zhu WG (2006) Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol 26:2782-2790
20. Carlisi D, Vassallo B, Lauricella M, Emanuele S, D'Anneo A, Di Leonardo E, Di Fazio P, Vento R, Tesoriere G (2008) Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects. Int J Oncol 32:177-184 (Pubitemid 351176076)
21. Condorelli F, Gnemmi I, Vallario A, Genazzani AA, Canonico PL (2008) Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br J Pharmacol 153:657-668 (Pubitemid 351271755)
22. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT (2005) Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res 65:1918-1924 (Pubitemid 40478621)
23. Tokalov SV, Abolmaali ND (2010) Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment. BMC Cancer 10:57
24. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ Jr, Kohn KW (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growthinhibitory potency of 123 anticancer agents. Cancer Res 57:4285-4300 (Pubitemid 27413438)
25. Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtesek B, Kaye SB (1993) Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 55:678-684 (Pubitemid 23328959)
26. Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70:440-446
27. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3:1101-1108 (Pubitemid 351818697)
28. Xu WS, Parmigiani RB, Marks PA (2007) Histone deacetylase inhibitors: Molecular mechanisms of action. Oncogene 26:5541-5552 (Pubitemid 47255934)
29. Harms KL, Chen X (2007) Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res 67:3145-3152 (Pubitemid 46724851)
30. Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW (2006) Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res 66:3169-3176
31. Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J (2006) MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem 281:33030-33035 (Pubitemid 46036685)
32. Wade M, Wong ET, Tang M, Stommel JM, Wahl GM (2006) Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem 281:33036-33044 (Pubitemid 46036686)
33. Hu B, Gilkes DM, Chen J (2007) Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res 67:8810-8817 (Pubitemid 47437457)
34. Nakano K, Mizuno T, Sowa Y, Orita T, Yoshino T, Okuyama Y, Fujita T, Ohtani-Fujita N, Matsukawa Y, Tokino T, Yamagishi H, Oka T, Nomura H, Sakai T (1997) Butyrate activates the WAF1/ Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem 272:22199-22206 (Pubitemid 27382850)
35. Vrana JA, Decker RH, Johnson CR,Wang Z, Jarvis WD, Richon VM, EhingerM, Fisher PB, Grant S (1999) Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 18:7016-7025 (Pubitemid 30028872)
36. Coll-Mulet D, Iglesias-Serret D, Santidrian AF, Cosialls AM, de Frias M, Castano E, Campas C, Barragan M, de Sevilla AF, Domingo A, Vassilev LT, Pons G, Gil J (2006) MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 107:4109-4114 (Pubitemid 43726820)
37. Barbieri E, Mehta P, Chen Z, Zhang L, Slack A, Berg S, Shohet JM (2006) MDM2 inhibition sensitizes neuroblastoma to chemotherapyinduced apoptotic cell death. Mol Cancer Ther 5:2358-2365 (Pubitemid 44530473)
38. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A, Johnson D, Wilson M, Rodriguez-Galindo C, Quarto M, Francoz S, Mendrysa SM, Guy RK, Marine JC, Jochemsen AG, Dyer MA (2006) Inactivation of the p53 pathway in retinoblastoma. Nature 444:61-66 (Pubitemid 44684754)
39. Secchiero P, Zerbinati C, di Iasio MG, Melloni E, Tiribelli M, Grill V, Zauli G (2007) Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab 8:395-403 (Pubitemid 46780067)
40. Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, Raje NS, Munshi NC, Chauhan D, Hideshima T, Buon L, Clynes M, O'Gorman P, Richardson PG, Mitsiades CS, Anderson KC, Mitsiades N (2009) Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res 15:7153-7160
41. Kurosu T, Wu N, Oshikawa G, Kagechika H, Miura O (2010) Enhancement of imatinib-induced apoptosis of BCR/ABLexpressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway. Apoptosis 15:608-620
42. Kranz D, Dobbelstein M (2006) Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy. Cancer Res 66:10274-10280 (Pubitemid 44799744)
43. Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N (2009) A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA 106:3964-3969
44. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ, Johnstone RW (2001) The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 98:10833-10838 (Pubitemid 32878706)
45. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S, Pelicci PG (2005) Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11:71-76 (Pubitemid 40215840)
46. Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L,Williams S,Wiegmans AP, Dear AE, Scott CL, PellegriniM, WeiA, RichonVM,Marks PA, LoweSW, Smyth MJ, Johnstone RW (2007) Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA 104:8071-8076 (Pubitemid 47185877)
47. Sharma SV, Lee DY, Li B, QuinlanMP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, Wong KK, Brandstetter K, Wittner B, Ramaswamy S, Classon M, Settleman J (2010) A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141:69-80